{"organizations": [], "uuid": "443da84aea797703eb4fb61e8488fbcf4b9f85d1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180524.html", "section_title": "Archive News &amp; Video for Thursday, 24 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-us-fda-grants-fast-track-designati/brief-u-s-fda-grants-fast-track-designation-for-krystal-biotechs-kb103-idUSASC0A3JW", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.983, "site_type": "news", "published": "2018-05-24T20:33:00.000+03:00", "replies_count": 0, "uuid": "443da84aea797703eb4fb61e8488fbcf4b9f85d1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-us-fda-grants-fast-track-designati/brief-u-s-fda-grants-fast-track-designation-for-krystal-biotechs-kb103-idUSASC0A3JW", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103", "locations": [], "entities": {"persons": [{"name": "krystal biotech", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "krystal biotech inc", "sentiment": "negative"}, {"name": "krystal biotech’s", "sentiment": "neutral"}, {"name": "epidermolysis bullosa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 24 (Reuters) - Krystal Biotech Inc:\n* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR KRYSTAL BIOTECH’S KB103 FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-24T20:33:00.000+03:00", "crawled": "2018-05-25T16:10:11.000+03:00", "highlightTitle": ""}